Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Corticosteroids|Corticosteroid]] (7) ·
[[:Category:Glucocorticoids|Glucocorticoid]] (4) ·
[[:Category:Antibacterials|Antibacterial]] (3) ·
[[:Category:Inhaled_corticosteroids|Inhaled corticosteroid (ICS)]] (3) ·
[[:Category:Analgesics|Analgesic]] (2) ·
[[:Category:Antiemetics|Antiemetic]] (2) ·
[[:Category:Antifungals|Antifungal]] (2) ·
[[:Category:Antimuscarinics|Antimuscarinic]] (2) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist]] (2) ·
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] (2) ·
[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID)]] (2) ·
[[:Category:Topical_antifungals|Topical antifungal]] (2)
mechanism:
None (33) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) ·
Small-molecule CGRP receptor antagonist; intranasal formulation (1) ·
Tropane alkaloids: hyoscyamine (dominant; the racemic form is atropine), scopolamine. Competitive muscarinic antagonism. (1) ·
'"`UNIQ--vote-0000001D-QINU`"' Major Beers-list concern in elderly patients for cognitive and fall risks. CYP2D6 substrate. At massive overdose, also produces sodium channel blockade with cardiac toxicity'"`UNIQ--ref-0000001E-QINU`"'.
'"`UNIQ--effect-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-00000037-QINU`"' Hypertonic 3% is the standard urgent treatment of severely symptomatic hyponatremia'"`UNIQ--ref-00000038-QINU`"'. (1) ·
'"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1) ·
'"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) ·
'"`UNIQ--vote-00001014-QINU`"' Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. The dipropionate, valerate, and augmented dipropionate ester forms determine topical potency (high to super-high)'"`UNIQ--ref-00001015-QINU`"'. (1) ·
'"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1) ·
'"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1) ·
'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'. (1)
uses:
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (3) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (2)
starting dose:
preparations:
fda max:
routes: (Click arrow to add another value)
onset:
None (1) ·
10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) (1) ·
15 minutes (1) ·
15-30 minutes (oral); 1-2 minutes (IV) (1) ·
15-60 minutes (oral); 1-5 minutes (IV); 4-10 minutes (rectal or intranasal) (1) ·
20–60 min (oral) (1) ·
30 minutes (IM); 30-60 minutes (oral) (1) ·
30-60 min (IR oral); 2-3 days to steady state (transdermal patch) (1) ·
30-60 minutes (oral); slower for topical (1) ·
30-60 minutes (PO) (1) ·
<1 minute (IV); 1-2 minutes (infiltration); 30+ minutes (patch on adult skin, faster on thinner pediatric skin) (1) ·
Bronchodilation 15-30 minutes (1) ·
Caries reduction over months to years of consistent use (1) ·
Clinical and mycologic cure follows the full course; nail clearance over months of regrowth (1) ·
Cognitive effect emerges gradually over weeks to months; ceiling effect at the therapeutic dose (1) ·
Days (2) ·
Days for calcium effect; weeks for PTH suppression (1) ·
Days for dermatophyte clearance; nail clearance over months (1) ·
Hours (5) ·
Hours to days (1) ·
Hours to days for inflammation; substantial improvement within 1 week (1) ·
Immediate (IV) (1) ·
Inhaled: bronchial effect 1-2 weeks; nasal: symptom relief 12-24 hours; topical: hours (1) ·
Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks (1) ·
Intranasal: symptom relief 12-24 hours; inhaled: bronchial effect 1-2 weeks (1) ·
IV/IM 1-3 minutes; PO 30-60 minutes (1) ·
Minutes (1) ·
Pain relief reported within 15 min in trials (1) ·
Reticulocyte response at 3-5 days; neurologic recovery weeks to months (and may be incomplete if longstanding) (1) ·
SL/spray: 1-3 minutes; IV: minutes; patch: 30-60 minutes (1) ·
Sleep effect from first dose; antidepressant effect over 1-4 weeks (1) ·
Symptom relief within 24-48 hours of starting episodic treatment (1) ·
Symptom relief within 30-60 minutes (1) ·
Symptom relief within days (1) ·
Topical hours; intra-articular days to weeks (1) ·
Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) ·
Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) ·
Vasomotor relief 2-4 weeks; bone density gains over months (1) ·
Visible lightening at 4-12 weeks (1)
duration:
None (1) ·
12 hours (1) ·
12-24 hours (1) ·
12-24 hours per dose (1) ·
2-4 hours; headache recurrence rate ~20-30% within 24 hours (1) ·
24 hours (2) ·
24 hours (0.7% formulation); 8-12 hours (lower-strength) (1) ·
24 hours (HS dosing) (1) ·
24 hours (once-daily dosing) (1) ·
30-90 minutes (infiltration without epinephrine); 90-200 minutes (with epinephrine); 12 hours (patch) (1) ·
4-6 hours (4) ·
6-24 hours (parent); much longer when accounting for the long-lived active metabolites (1) ·
6-8 hours (2) ·
6-8 hours (IR oral); 12-24 hours (ER) (1) ·
8 hours per oral dose (1) ·
8-12 hours (1) ·
8-12 hours (IR); ~7 days (transdermal patch) (1) ·
Biologic 36-54 hours (long-acting) (1) ·
Biologic ~8-12 hours (short-acting) (1) ·
Hours per application (5) ·
Hours per dose (much shorter biologic effect than ergocalciferol/cholecalciferol because it is the already-active form, not the storage form) (1) ·
Hours per topical application (1) ·
Hours to days per application (1) ·
Intra-articular 3-6 months (depot effect of acetonide microcrystals) (1) ·
IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) ·
IR: 6-10 hours; ER: 24 hours (1) ·
N/A (2) ·
N/A (replacement) (1) ·
Persistent activity 6+ hours (residual binding to skin and oral surfaces) (1) ·
Roughly 20-25% of an IV bolus remains intravascular at 1 hour (1) ·
Route- and formulation-dependent (1) ·
SL: 30 minutes; patch: 12-14 hours; IV continuous (1) ·
Variable (1) ·
~48 h sustained pain freedom in responders (1)
halflife:
bioavailability:
pregnancy:
None (3) ·
Generally considered safe (minimal systemic absorption).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2) ·
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
legal:
OTC (Astepro 0.15%) and [[USLegal:Prescription only|Rx-only]] (other intranasal, ophthalmic, Dymista) in US (1) ·
OTC (intranasal Flonase) and [[USLegal:Prescription only|Rx-only]] (inhaled, topical) in US (1) ·
OTC (intranasal Rhinocort Allergy) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (low-dose topicals) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (low/mid-dose oral) and [[USLegal:Prescription only|Rx-only]] (injection, intranasal) in US (1) ·
OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) ·
OTC (lower-concentration washes) and [[USLegal:Prescription only|Rx-only]] (Peridex oral rinse, ChloraPrep) in US (1) ·
OTC (lowest-strength topicals) and [[USLegal:Prescription only|Rx-only]] (higher strengths, injectable) in US (1) ·
OTC (most dentifrice and rinse) and [[USLegal:Prescription only|Rx-only]] (high-concentration paste/gel, supplements) in US (1) ·
OTC (Nasonex 24HR) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (ophthalmic ointment) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US (1) ·
OTC (topical) and [[USLegal:Prescription only|Rx-only]] (oral) in US (1) ·
OTC (transdermal patch in women) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
Plant unrestricted; pharmaceutical atropine Rx-only (1) ·
Rx (1) ·
Schedule II (1) ·
[[USLegal:Over-the-counter|OTC]] for most oral and topical formulations; [[USLegal:Prescription only|Rx-only]] for injectable (1) ·
[[USLegal:Prescription only|Rx-only]] for most formulations; some low-concentration topical formulations are [[USLegal:Over-the-counter|OTC]] (4% cream) (1) ·
[[USLegal:Prescription only|Rx-only]] for oral and most topical formulations in US; Voltaren Arthritis Pain 1% gel switched to [[USLegal:Over-the-counter|OTC]] in 2020 (1) ·
[[USLegal:Prescription only|Rx-only]] for parenteral formulations; OTC for oral, nasal, and many nebulizer products (1) ·
[[USLegal:Prescription only|Rx-only]] in US (16) ·
[[USLegal:Prescription only|Rx-only]] in US (the veterinary preparations are not for human use) (1) ·
[[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns) (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for '''tardive dyskinesia''' (irreversible movement disorder), driving the 12-week chronic-use limit'"`UNIQ--ref-00000EFB-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for Clostridioides difficile colitis (one of the most C. difficile-inducing antibiotic classes)'"`UNIQ--ref-00001444-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-00000022-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, like guanfacine and unlike the psychostimulant alternatives for ADHD'"`UNIQ--ref-00000028-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000028-QINU`"' (1)
Showing below up to 50 results in range #1 to #50.